DNAzyme-based Faithful Probing and Pulldown to Identify Candidate Biomarkers of Low Abundance.

Qinqin Hu,Zongxuan Tong,Ayimukedisi Yalikong,Li-Ping Ge,Qiang Shi,Xinyu Du,Pu Wang,Xi-Yu Liu,Wuqiang Zhan,Xia Gao,Di Sun,Tong Fu,Dan Ye,Chunhai Fan,Jie Liu,Yun-Shi Zhong,Yi-Zhou Jiang,Hongzhou Gu
DOI: https://doi.org/10.1038/s41557-023-01328-5
IF: 24.274
2024-01-01
Nature Chemistry
Abstract:Biomarker discovery is essential for the understanding, diagnosis, targeted therapy and prognosis assessment of malignant diseases. However, it remains a huge challenge due to the lack of sensitive methods to identify disease-specific rare molecules. Here we present MORAC, molecular recognition based on affinity and catalysis, which enables the effective identification of candidate biomarkers with low abundance. MORAC relies on a class of DNAzymes, each cleaving a sole RNA linkage embedded in their DNA chain upon specifically sensing a complex system with no prior knowledge of the system’s molecular content. We show that signal amplification from catalysis ensures the DNAzymes high sensitivity (for target probing); meanwhile, a simple RNA-to-DNA mutation can shut down their RNA cleavage ability and turn them into a pure affinity tool (for target pulldown). Using MORAC, we identify previously unknown, low-abundance candidate biomarkers with clear clinical value, including apolipoprotein L6 in breast cancer and seryl-tRNA synthetase 1 in polyps preceding colon cancer.
What problem does this paper attempt to address?